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Background. Among gynecologic cancers, ovarian cancer is the second most common and has the highest death rate. Cancer
is a genetic disorder and arises due to the accumulation of somatic mutations in critical genes. An understanding of the
genetic basis of ovarian cancer has implications both for early detection and for therapeutic intervention in this population of
patients. Methodology/Principal Findings. Fifteen ovarian cancer cell lines, commonly used for in vitro experiments, were
screened for mutations using bidirectional direct sequencing in all coding regions of BRAF, MEK1 and MEK2. BRAF mutations
were identified in four of the fifteen ovarian cancer cell lines studied. Together, these four cell lines contained four different
BRAF mutations, two of which were novel. ES-2 had the common B-Raf p.V600E mutation in exon 15 and Hey contained an
exon 11 missense mutation, p.G464E. The two novel B-Raf mutants identified were a 5 amino acid heterozygous deletion
p.N486-P490del in OV90, and an exon 4 missense substitution p.Q201H in OVCAR 10. One of the cell lines, ES-2, contained a
mutation in MEK1, specifically, a novel heterozygous missense substitution, p.D67N which resulted from a nt 199 GRA
transition. None of the cell lines contained coding region mutations in MEK2. Functional characterization of the MEK1 mutant
p.D67N by transient transfection with subsequent Western blot analysis demonstrated increased ERK phosphorylation as
compared to controls. Conclusions/Significance. In this study, we report novel BRAF mutations in exon 4 and exon 12 and
also report the first mutation in MEK1 associated with human cancer. Functional data indicate the MEK1 mutation may confer
alteration of activation through the MAPK pathway. The significance of these findings is that BRAF and MEK1/2 mutations may
be more common than anticipated in ovarian cancer which could have important implications for treatment of patients with
this disease and suggests potential new therapeutic avenues.
Citation: Estep AL, Palmer C, McCormick F, Rauen KA (2007) Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications
for Therapy. PLoS ONE 2(12): e1279. doi:10.1371/journal.pone.0001279
INTRODUCTION
Ovarian cancer is the second most common gynecologic cancer in
the United States affecting approximately 22,000 women each
year causing an estimated 15,200 deaths [1]. Cancer is a genetic
disorder arising from the accumulation of somatic mutations in
genes involved in critical cellular pathways. These mutations
typically result in proteins which exhibit their oncogenic effect by
altering signaling through vital transduction networks, or in
haploinsufficiency of critical tumor suppressor proteins.
Understanding the genetic basis of ovarian cancer has
implications both for early detection, as well as for therapeutic
intervention in this population of patients. Genes which have been
found somatically mutated in ovarian cancer include KRAS [2–5],
NRAS [2], PIK3CA [5–9], PTEN [5,10,11], TP53 [5,12,13] and
BRAF [2–4]. B-Raf, the protein product of BRAF, is a serine/
threonine protein kinase and the first in the mitogen-activated
protein kinase (MAPK) cascade which is one of the many
downstream effector pathways of Ras. Extracellular stimuli leads
to the activation of Ras, which in turn activates Raf (A-Raf, B-Raf,
and/or C-Raf-1). Raf then phosphorylates and activates MEK1
and/or MEK2 (MAPK kinase). MEK1 and MEK2 are threonine/
tyrosine kinases with both isoforms having the ability to
phosphorylate and activate ERK1 and ERK2 (MAPK). ERK,
once activated by MEK, has numerous cytosolic and nuclear
substrates [14]. Aberrant upstream signaling resulting in hyper-
activated ERK plays a key role in the pathogenesis and
progression of approximately 30% of human cancers, including
ovarian cancer [15]. As a result, this pathway has been an
attractive target for the development of small molecule inhibitors
for the treatment of cancer [16].
Genes comprising the MAPK pathway, BRAF, MEK1 and
MEK2, were systematically scanned for mutations in 15 ovarian
cancer cell lines using bidirectional direct sequencing of all exons.
Previous reports have demonstrated that B-Raf is mutated in
approximately 28–37% of low grade serous carcinomas [3,17].
With this information, our search was expanded to include MEK1
and MEK2, two genes along with BRAF, which we have recently
determined to be causal for cardio-facio-cutaneous (CFC)
syndrome (MIM 115150), a multiple congenital anomaly syn-
drome whereby individuals have characteristic craniofacial
dysmorphia, heart defects and ectodermal anomalies [18].
Interestingly, unlike germline mutations identified in CFC
syndrome, no somatic mutations have ever been identified in
MEK1/2 in any cancer type. In our analysis, novel BRAF
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PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1279mutations were identified in exon 4 and exon 12 of two separate
cell lines. In addition, we report the first functional mutation in
MEK1 associated with human cancer. The significance of these
findings is that BRAF and MEK1/2 mutations may be more
common than previously recognized in ovarian cancer, which
could have important implications for the treatment of patients
with ovarian cancer.
RESULTS
BRAF and MEK1 Mutations
Genomic DNA from 15 ovarian cancer cell lines was screened for
BRAF mutations in coding exons 1–18. Four mutations were
identified in four individual cell lines: OVCAR 10, OV90, Hey
and ES-2 (Figure 1). None of the other cell lines had BRAF
mutations. Two of the four BRAF mutations identified were novel.
OVCAR 10 contained a nt 603 GRT transversion causing a
heterozygous missense substitution p.Q201H in exon 4 (Figure 1A).
OV90 contained a novel heterozygous 5 amino acid deletion,
p.N486-P490del, in exon 12 (Figure 1B). In addition to the two
novel BRAF mutations identified, two additional mutations which
have been previously reported in cancer were identified. Hey
contained a nt 1391 GRA transition resulting in an exon 11
missense mutation, p.G464E (Figure 1C). The electropherogram
demonstrated loss of heterozygosity at this locus. ES-2 contained
an exon 15, TRA transversion at nt 1799, substituting glutamic
acid for valine at position 600 (p.V600E) (Figure 1D). None of
these mutations were identified in the controls.
All eleven coding exons of MEK1 and MEK2 were also sequenced
in the same cell lines and controls. One mutation in MEK1 was
identified in ES-2 consisting of a novel heterozygous missense
substitution, p.D67N, which resulted from a nt 199 GRA transition
(Figure 1E). No other nonsynonymous substitutions in MEK1 were
identified. All eleven coding exons of MEK2 were sequenced and no
nonsynonymous substitutions were identified.
Nucleotide Variation
In addition to these mutations, a total of four different synonymous
single nucleotide polymorphisms (SNPs) were identified in BRAF
(Table 1), MEK1 (Table 2), and MEK2 (Table 3). Three of these
four SNPs were found in five or more of the fifteen cell lines and
have been previously reported (www.ncbi.nlm.nih.gov/SNP/). In
order of frequency, the three synonymous database SNPs include:
i) MEK2 p.I220I (rs10250) present in 11 of the 15 cell lines (73%),
ii) BRAF p.G634G (rs9648696) found in six of the 15 cell lines
(40%) and, iii) MEK2 p.D151D (rs17851657) identified in five of
the 15 cell lines (33%). There was one uniquely identified MEK1
SNP in OVCAR 10 resulting from a nt 348 heterozygous GRA
transition in exon 3, p.Q113Q (Table 2). All synonymous SNPs
were characterized by SIFT (Sorting Intolerant From Tolerant)
and determined to be tolerated.
Functional Characterization of Mutants
SIFT was utilized to characterize the functional significance of the
nonsynonymous amino acid substitutions identified in B-Raf and
MEK1. B-Raf p.G464E, p.N486-P490del, p.V600E and MEK1
p.D67N were predicted to be deleterious substitutions causing an
alteration of protein function, whereas B-Raf p.Q201H was
predicted to be tolerated.
To corroborate the functional alteration of the novel MEK1
p.D67N mutant identified in ES-2, transient transfection of HEK
293T cells with subsequent Western blot analysis demonstrated
increased kinase activity as measured by ERK phosphorylation
(Figure 2). The MEK1 p.D67N mutant had increased ERK
Figure 1. Electropherograms of BRAF and MEK1 mutations compared
to normal controls. Four BRAF mutations were identified in four
individual cell lines. A) OVCAR 10 contained a nt 603 GRT transversion
causing a heterozygous missense substitution p.Q201H in exon 4. B)
OV90 contained a novel heterozygous deletion starting at nt 1457
(arrow) resulting in a 5 amino acid deletion, p.N486-P490del, in exon 12.
C) Hey contained a nt 1391 GRA transition resulting in loss of
heterozygosity. D) ES-2 contained an exon 15, TRA transversion at nt
1799, substituting glutamic acid for valine at position 600 (p.V600E). E)
A nt 199 GRA transition in MEK1, exon 2 resulted in a heterozygous
missense substitution, p.D67N.
doi:10.1371/journal.pone.0001279.g001
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PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1279phosphorylation compared to wildtype MEK1. The level of ERK
phosphorylation was lower than the CFC MEK1 p.Y130C mutant
which is known to have a high level of activity (positive control).
DISCUSSION
Altered signaling through the MAPK pathway in cancer often
results from mutations in upstream components of ERK, including
K-Ras, N-Ras, H-Ras, C-Raf-1 and B-Raf [15]. Molecular studies
of ovarian cancer cell lines and tumor specimens have identified
genetic mutations in some of these genes, KRAS, NRAS and BRAF ,
which result in the alteration of signaling through this critical
pathway [2,19–23].
Somatic mutations in BRAF have been reported at a high
frequency in numerous cancers including melanoma, thyroid,
colorectal and ovarian. Approximately 70 missense mutations
affecting 34 codons have been reported (www.sanger.ac.uk/
genetics/CGP/cosmic). In cancer, the majority of somatic BRAF
mutations result in missense substitutions found in, but not limited
to, exon 11 (the glycine-rich loop) and exon 15 (the activation
segment) in the protein kinase domain [24]. One missense
Table 1. BRAF sequence variations identified in ovarian cancer cell lines.
..................................................................................................................................................
Cell Line Exon Nucleotide Mutation Amino Acid Mutation dbSNP* Predicted Protein Function**
OVCAR 10 4 603 G.GT p.Q201H N/A tolerated
Hey 11 1391 G.AA p.G464E N/A affected
OV90 12 D1457-1471 p.N486-P490 del N/A affected
ES-2 15 1799 T.TA p.V600E N/A affected
A2780 16 1929 A.AG p.G643G rs9648696 tolerated
OV90 16 1929 A.AG p.G643G rs9648696 tolerated
A1847 16 1929 A.AG p.G643G rs9648696 tolerated
IGROV 1 16 1929 A.AG p.G643G rs9648696 tolerated
2008 16 1929 A.GG p.G643G rs9648696 tolerated
OVCAR 10 16 1929 A.GG p.G643G rs9648696 tolerated
*www.ncbi.nlm.nih.gov/SNP/
**blocks.fhcrc.org/sift/SIFT.html
doi:10.1371/journal.pone.0001279.t001
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Table 2. MEK1 sequence variations identified in ovarian cancer
cell lines.
......................................................................
Cell Line Exon
Nucleotide
Mutation
Amino Acid
Mutation dbSNP*
Predicted Protein
Function **
ES-2 2 199 G.GA p.D67N N/A affected
OVCAR 10 3 348 G.GA p.Q116Q none tolerated
*www.ncbi.nlm.nih.gov/SNP/
**blocks.fhcrc.org/sift/SIFT.html
doi:10.1371/journal.pone.0001279.t002
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Table 3. MEK2 synonymous SNPs identified in ovarian cancer cell lines.
..................................................................................................................................................
Cell Line Exon Nucleotide Mutation Amino Acid Mutation dbSNP* Predicted Protein Function **
OVCAR 3 4 453 C.CT p.D151D rs17851657 tolerated
SKOV 3 4 453 C.CT p.D151D rs17851657 tolerated
ES-2 4 453 C.CT p.D151D rs17851657 tolerated
2008 4 453 C.CT p.D151D rs17851657 tolerated
Hey 4 453 C.CT p.D151D rs17851657 tolerated
OVCAR 3 6 660 A.AC p.I220I rs10250 tolerated
SKOV 3 6 660 A.CC p.I220I rs10250 tolerated
A2780 6 660 A.AC p.I220I rs10250 tolerated
OV90 6 660 A.CC p.I220I rs10250 tolerated
ES-2 6 660 A.CC p.I220I rs10250 tolerated
TOV-21g 6 660 A.CC p.I220I rs10250 tolerated
OVCAR 5 6 660 A.CC p.I220I rs10250 tolerated
2008 6 660 A.AC p.I220I rs10250 tolerated
OVCAR 10 6 660 A.AC p.I220I rs10250 tolerated
PEO1 6 660 A.AC p.I220I rs10250 tolerated
Hey 6 660 A.AC p.I220I rs10250 tolerated
*www.ncbi.nlm.nih.gov/SNP/
**blocks.fhcrc.org/sift/SIFT.html
doi:10.1371/journal.pone.0001279.t003
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Mutations in Ovarian Cancer
PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1279mutation in exon 15 resulting in a missense substitution, B-Raf
p.V600E, accounts for over 90% of BRAF mutations identified in
human cancer. The crystal structure of B-Raf shows that the
activation segment is held in an inactive conformation by association
with the G-loop. Mutations in these two regions, the glycine-rich
loop and the activation segment, are believed to disrupt this
interaction, converting B-Raf into its active conformation [25].
In addition to somatic mutations, germline mutations in BRAF
have recently been identified as causing CFC syndrome, a multiple
congenital anomaly disorder whereby individuals have character-
istic craniofacial dysmorphisms, cardiac defects, ectodermal
anomalies and developmental delay [18,26]. Most of the
mutations in CFC syndrome fall outside the exon 11 and exon
15 protein kinase domain. The most common causative CFC
mutation, p.Q257R, resides in exon 6 of the cysteine-rich domain.
Like most cancer-causing mutations in BRAF, biochemical studies
have determined that most novel CFC B-Raf mutant proteins
have increased kinase activity relative to the kinase activity of wild-
type B-Raf [18,26]. These studies punctuate the fact that BRAF
mutations occur not only somatically but also in the germline, and
that mutations that confer increased kinase activity are not
restricted to those typically associated with cancer.
Bidirectional sequencing of all the coding exons of BRAF in 15
well-characterized and highly utilized ovarian cancer cell lines
identified four cell lines with BRAF mutations. Only one cell line
had the common exon 15 BRAF mutation. ES-2 which is derived
from ovarian clear cell carcinoma [27] had the common
heterozygous p.V600E missense mutation. Previous reports have
demonstrated that B-Raf is mutated most commonly in low grade
ovarian serous carcinomas with a frequency of approximately 28–
37% and that all mutations are the common B-Raf p.V600E
variant [3,17]. Interestingly, the two serous-derived cell lines
examined in this study (Hey and OV90) did not have the common
B-Raf p.V600E mutation; however, both did contain BRAF
mutations. Hey, derived from a papillary serous carcinoma [28],
contained an exon 11 missense mutation, p.G464E. This missense
mutation has been described previously (www.sanger.ac.uk/
genetics/CGP/cosmic) and is also a codon which is mutated in
CFC syndrome ([29]; Rauen, unpublished data). OV90 which is
derived from a serous adenocarcinoma [30] contained a novel
mutation in exon 12 resulting in a heterozygous five amino acid
deletion, p.N486-P490del. Although extremely rare, somatic exon
15 B-Raf in-frame deletion-insertions have been reported in
cancer [31,32]. In addition, we identified two CFC individuals
with small in-frame deletions in exon 11 (Rauen, unpublished
data). Finally, OVCAR 10, which is derived from a human
ovarian epithelial cancer, had a unique heterozygous missense
substitution p.Q201H in exon 4. This nonsynonymous SNP has
not been identified in cancer or CFC syndrome and was
determined to be tolerated by SIFT, so perhaps B-Raf p.Q210H
represents a rare polymorphism.
Only two of the ovarian cancer cell lines had mutations in the
typically affected exon 11/15 regions in the B-Raf protein kinase
domain. This finding raises the possibility that cancer-associated
BRAF mutations outside of exon 11/15 may be more common
than anticipated. Since the vast majority of BRAF mutation survey
studies published are restricted to exons 11 and 15, other possible
mutations outside these regions may be overlooked.
To explore the functional significance of these novel B-Raf
mutants, all those identified in this study were analyzed by SIFT
(http://blocks.fhcrc.org/sift/SIFT.html), an online mutation anal-
ysis program that predicts the functional consequence of
nonsynonymous amino acid substitutions [33,34]. All BRAF
mutations identified were predicted to have altered protein
function except for p.Q201H. The functional significance of
BRAF coding mutations in exons other than 11 and 15 is
supported by biochemical studies of novel germline mutations
identified in CFC. Like somatic mutations, most CFC germline
mutations confer an increased kinase activity, while some are
kinase impaired. However, all CFC mutations which have been
biochemically characterized alter protein function to some extent
([18,26]; Rauen, unpublished data).
B-Raf has only two known downstream effectors, MEK1 and
MEK2. In an effort to characterize the mutation spectrum of the
MAPK pathway in ovarian cancer, we also sequenced MEK1/2
and identified a novel MEK1 heterozygous missense substitution,
p.D67N, in ES-2 which resulted from a nt 199 GRA transition.
This is the first identified functional MEK mutation associated
with cancer and does not represent a rare polymorphism in that
this mutation was not identified in 40 normal controls (80 alleles)
or in 52 CFC individuals (104 alleles) we have sequenced to date (
[18]; Rauen, unpublished data). Interestingly, although we had not
identified this MEK1 p.D67N mutant in our CFC cohort, this
same MEK1 mutation has recently been reported as a germline
mutation in CFC syndrome [29]. In addition to a MEK1 mutation,
ES-2 also had a B-Raf p.V600E missense substitution. These two
mutations may have been co-operating tumorigenic events. What
makes this finding particularly interesting is the fact that previous
sequencing studies of the MEK1/2 protein kinase domain failed to
identify any mutations in gliomas, testicular germ cell tumors,
breast cancer and lung cancer [35–38]. Notably, the p.D67N in
ES-2 falls outside the protein kinase domain which spans from AA
68-271 (www.ensembl.org/Homo_sapiens). Many germline CFC
mutations are located 5’ of the protein kinase domain ([18,29,39];
Rauen, unpublished data). Functional studies of these novel CFC
mutants have demonstrated increased activity in vitro over wildtype
MEK in stimulating ERK phosphorylation, but these CFC
mutants are not as active as an artificially generated constitutively
active MEK mutant ([18]; Rauen, unpublished data). Other
studies have demonstrated that alteration of the N-terminus of
MEK increases the basal kinase activity implicating an important
regulatory role along with substrate recognition [40–42].
To assess the functional consequence of MEK1 p.D67N, this
amino acid substitution was analyzed by SIFT and found to be
Figure 2. Functional characterization of the MEK1 p.D67N mutant
identified in ES-2. Human embryonic kidney 293T cells were transiently
transfected with empty vector, wild-type MEK1, MEK1 p.Y130C (positive
control mutant which has known high activity level[18]) and the MEK1
p.D67N mutant. ERK (p44 ERK1 and p42 ERK2) phosphorylation was
assayed by Western blotting using phospho-specific antibodies. The
p.D67N MEK1 mutant had increased ERK phosphorylation compared to
the level induced by empty vector and wildtype MEK1. The level of ERK
phosphorylation induced by p.D67N MEK1 is slightly less than the CFC
MEK1 p.Y130C mutant which is known to have increased activity [18].
Myc-tagged MEK1 is shown for transfection efficiency and total ERK is
shown as a loading control.
doi:10.1371/journal.pone.0001279.g002
Mutations in Ovarian Cancer
PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1279functionally affected. To corroborate this information, MEK1
p.D67N was transiently transfected into HEK 293T cells, and
ERK phosphorylation was measured by Western blot analysis.
The MEK1 p.D67N mutant is activating as demonstrated by
increased ERK phosphorylation as compared to empty vector and
wildtype MEK1, two controls which do not activate ERK.
However, the level of ERK phosphorylation for p.D67N is less
than the positive control CFC MEK1 p.Y130C mutant [18].
In addition to BRAF and MEK1 mutations, several synonymous
database SNP were also identified. B-Raf p.G634G (rs9648696)
was identified in 40% of the 15 cell lines, MEK2 p.I220I (rs10250)
was present in 73% and MEK2 p.D151D (rs17851657) was
identified in 33% of the cell lines. These synonymous database
SNPs were present at a frequency which is comparable to that
previously reported (http://www.ncbi.nlm.nih.gov/SNP/snp;
[43]). There was one uniquely identified MEK1 SNP in OVCAR
10 resulting from a nt 348 heterozygous GRA transition in exon
3, p.Q113Q. All synonymous SNPs were characterized by SIFT
and determined to be tolerated.
Our findings emphasize that mutations which alter function of
the MAPK pathway play an important role in ovarian cancer [15].
In addition, the identification of mutations in key MAPK pathway
components will be important in determining the responsiveness of
the cancer to therapeutics, the aggressive and metastatic behavior
of the tumor and the prognosis of the patient. Four of 15 (26%) cell
lines in this study had BRAF mutations and 1 of 15 (7%) had a
MEK mutation. It is known that BRAF mutations have been
identified in certain types of ovarian cancer; however, mutations in
the downstream effectors of B-Raf including MEK1 and MEK2
may also be important contributors of ovarian cancer tumorigen-
esis. Defining the pathogenetics of ovarian cancer may enable the
use of targeted therapeutics, such as small molecule inhibitors of
MAPK pathway, which have recently begun to demonstrate great
promise [16]. In addition, a report indicates that cells with
activated B-Raf have enhanced, selective sensitivity to MEK
inhibitors [44]. Our results underscore the importance that further
characterization of the sensitivity of various BRAF and MEK
mutants to small molecule inhibition is an important avenue to
pursue towards the development of effective treatments for ovarian
cancer.
METHODS
Cell Lines and Isolation of Genomic DNA
Fifteen ovarian cancer cell lines, commonly used for in vitro
experiments, were screened for mutations: OVCAR 3, SKOV 3,
TOV-112d, A2780, OV90, ES-2, TOV-21g, Caov-3, A1847,
IGROV 1, OVCAR 5, 2008, OVCAR 10, PEO1 and Hey. Cell
pellets from each of these cell lines were kindly provided by Drs.
Charles Drescher and Beatrice Knudsen. Genomic DNA was
isolated from cell pellets using the QIAamp DNA Tissue kit
(Qiagen, Valencia, CA), according to the manufacturer’s instruc-
tions. Forty healthy human controls were included in this study.
Genomic DNA was isolated from peripheral blood lymphocytes
using the QIAamp DNA Blood Midi kit (Qiagen, Valencia, CA),
according to the manufacturer’s instructions. Control samples
were obtained under an approved institution review board from
the University of California San Francisco.
PCR and Bidirectional Sequencing
PCR primers were designed to amplify all coding exons and
intronic flanking regions of BRAF (NM_004333.2), MEK1
(NM_002755.2) and MEK2 (NM_030662.2) (Table 4 and
Table 5). For sequencing, the PCR primers were modified on
the 59 end to include M13 forward (GTAAAACGACGGC-
CAGT) and reverse (CAGGAAACAGCTATGACC) sequences.
PCR and sequencing were performed by Agencourt Bioscience
Corporation (Beverly, MA). Bidirectional sequencing was con-
ducted with ABI BigDye v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA) according to manufacturer’s
guidelines and run on an ABI3730xl capillary sequencing
instrument (Applied Biosystems, Foster City, CA).
Table 4. BRAF Sequencing Primers.
..................................................................................................................................................
Exon Forward Reverse bp
1 GCTCTCCGCCTCCCTTCC GGCCATTGTGTGTGTTTACG 405
2 GAAGGCTGCTCACCAAACC TCTTCCCAAATCTATTCCTAATCC 551
3 TGAAACTTAAAACCCTATCAACTGG GATGCCTCTATTTGCATGACC 500
4 TGTAGAAATGGTGTTGTATCTGACC CCAAATAAATCACACTCTGAATGG 515
5 TGTTACTAGCCCCTCGATAACC GCTTACAGGTACAAGCACACG 577
6 TCTTCCTTTCACCTCTGTTTCC AACAATCGTATGGAAGAAAAACC 589
7 TTTTAACAGTTGTTTCTGAGAATGG CCAGGAGATCCAAAAGAAAGC 528
8 AGCAGCTTTGGCAGTATTGG TCATCAGAGAGAAACCAGAAGC 518
9 CATTGGCAAGTGCTTCAAAA TTGGGTTTCTCTACACATTTTTCTC 355
10 AATGAGGCCCCTTTTTGG ATTCTGGACCAGCCTTTTCG 593
11 AGTAAGGGGATCTCTTCCTGTATCC TGCTGTGAACAGTTTTTATTTCC 416
12 CATGGAACAAACAAGGTTGG CATTGCATACTACTTAAAAGAATGTGG 511
13 TTTTTCTGACAACATTTTACCG CCAGCCATTAGTTAGCATCC 417
14 GGCTTGACTGGAGTGAAAGG AAAAGCAGGCTGTGGTATCC 506
15 GGAAAGCATCTCACCTCATCC TGGTTTCAAAATATTCGTTTTAAGG 566
16 GAATCAGGAATGGGAAGTGG TCTATCCTTCACGCTTACC 576
17 GAGAACCTTTGCCACAGTCC AATTTCTAGGTGTGCCACTGC 541
18 TGCTTTCTTGTAAAGTGTGATGG CCCGGAACAGAAAGTAAAGC 582
doi:10.1371/journal.pone.0001279.t004
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Sequencing data was analyzed using two sequence analysis programs,
PolyPhred Software v5.02 (University of Washington, Seattle, WA)
and SeqScapeH Software (Applied Biosystems, Foster City, CA). In
addition, manual review was conducted with Mutation Surveyor 3.00
(SoftGeneticsLLC,StateCollege,PA).Furtherevaluationofdetected
nucleotide mutations consisted of Sorting Intolerant From Tolerant
(SIFT; blocks.fhcrc.org/sift/SIFT.html)and screening againstknown
databases: NCBI, Cosmic, UniProtKB/Swiss-Prot and JSNP (www.
ncbi.nlm.nih.gov/SNP, www.sanger.ac.uk/genetics/CGP/cosmic/,
ca.expasy.org/sprot/, snp.ims.u-tokyo.ac.jp/).
Plasmids
Human MEK1 cDNA (Origene, Rockville, MD) was cloned into a
pcDNA3 vector with a Myc-tag at the N-terminus. The MEK1 nt
199 GRA transition was introduced using Quick-Change Site-
Directed Mutagenesis (Stratagene, La Jolla, CA) and verified by
direct sequencing.
Transient Transfections and Western Blot Analysis
Human embryonic kidney (HEK) 293T cells were seeded the day
before in six-well dishes and transfected, in duplicate, with 2 mg
total plasmid DNA and 5 ml of Lipofectamine 2000 (Life
Technologies, Carlsbad, CA) according to manufacturer’s instruc-
tions. Cells were serum-starved (0.5% fetal bovine serum) and
24 hours later lysed in buffer containing Protease and Phosphatase
Inhibitor cocktails (Sigma, St. Louis, MO). Expression levels of
myc-MEK, total ERK and phosphorylated ERK were analyzed
by Western blot. Myc (A-14) and p-ERK(E-4) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA), and p44/42
MAP Kinase antibody was purchased from Cell Signaling
Technology (Danvers, MA).
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